BioSpace News Archive

Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.

Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.

FORE Biotherapeutics announced new clinical data from the Phase 1/2a clinical trial for plixorafenib, a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations.

Novavax, Inc. announced that Nuvaxovid™ has been recommended for full Marketing Authorization for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union following a positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

The Insight Partners published latest research report on “Intracranial Pressure (ICP) Monitoring Devices Market Size Report, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering, Type, Application, End User, and Geography”,

According to our new research study on “Exoskeleton Robotic System Market Forecast to 2028 – COVID-19 Impact and Global Analysis

The Insight Partners published latest research study on “Coagulation Analyser Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Test, Technology, End Users, and Geography,

The Insight Partners published latest research study on “Diagnostic Imaging Market Forecast to 2028 – COVID-19 Impact and Global Analysis

According to the new market research report “Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Diagnosis, Treatment)

Biophytis SA announced that it has filed, through its pharmaceutical partner Intsel Chimos, an application for Early Access Authorisation in France with the French National Authority for Health for the use of Sarconeos [1] in the treatment of adult patients with a severe form of COVID-19, who are at risk of developing a critical form of the disease and for whom therapeutic alternatives are not appropriate.